{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:37:48Z","timestamp":1773387468132,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Telethon New Children\u2019s Hospital Research Fund","award":["F55541"],"award-info":[{"award-number":["F55541"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s13346-018-0482-z","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T13:19:40Z","timestamp":1517836780000},"page":"729-739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD)"],"prefix":"10.1007","volume":"8","author":[{"given":"Oliver D.","family":"Montagnat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham R.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen B.","family":"Bulitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Wyber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meru","family":"Sheel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan R.","family":"Carapetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-590X","authenticated-orcid":false,"given":"Ben J.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"key":"482_CR1","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1038\/nrdp.2015.84","volume":"2","author":"JR Carapetis","year":"2016","unstructured":"Carapetis JR, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Prim. 2016;2:15084.","journal-title":"Nat Rev Dis Prim"},{"issue":"9819","key":"482_CR2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0140-6736(11)61171-9","volume":"379","author":"E Marijon","year":"2012","unstructured":"Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012;379(9819):953\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(11)61171-9 .","journal-title":"Lancet"},{"issue":"8","key":"482_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJMoa1603693","volume":"377","author":"DA Watkins","year":"2017","unstructured":"Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, et al. Global, regional, and national burden of rheumatic heart disease, 1990-2015. N Engl J Med. 2017;377(8):713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603693 .","journal-title":"N Engl J Med"},{"issue":"11","key":"482_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","volume":"5","author":"JR Carapetis","year":"2005","unstructured":"Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685\u201394. https:\/\/doi.org\/10.1016\/S1473-3099(05)70267-X .","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"482_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.gheart.2013.08.011","volume":"8","author":"R Wyber","year":"2013","unstructured":"Wyber R, Taubert K, Marko S, Kaplan EL. Benzathine penicillin G for the management of RHD. Glob Heart. 2013;8(3):227\u201334. https:\/\/doi.org\/10.1016\/j.gheart.2013.08.011 .","journal-title":"Glob Heart"},{"issue":"6","key":"482_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1086\/516375","volume":"26","author":"DL Horn","year":"1998","unstructured":"Horn DL, Zabriskie JB, Austrian R, Cleary PP, Ferretti JJ, Fischetti VA, et al. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis. 1998;26(6):1341\u20135. https:\/\/doi.org\/10.1086\/516375 .","journal-title":"Clin Infect Dis"},{"issue":"2","key":"482_CR7","first-page":"1","volume":"13","author":"B Currie","year":"2006","unstructured":"Currie B. Benzathine penicillin\u2014down but not out. North Territ Dis Control Bull. 2006;13(2):1\u20133.","journal-title":"North Territ Dis Control Bull"},{"issue":"1","key":"482_CR8","first-page":"21","volume":"27","author":"K Holanda e Silva","year":"2006","unstructured":"Holanda e Silva K, et al. New insight about pharmaceutical dosage forms for benzathine penicillin G. Rev Ci\u00eanc Farm B\u00e1sica Apl. 2006;27(1):21\u20136.","journal-title":"Rev Ci\u00eanc Farm B\u00e1sica Apl"},{"issue":"10","key":"482_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025308","volume":"6","author":"MP Broderick","year":"2011","unstructured":"Broderick MP, Hansen CJ, Russell KL, Kaplan EL, Blumer JL, Faix DJ. Serum penicillin G levels are lower than expected in adults within two weeks of administration of 1.2 million units. PLoS One. 2011;6(10):e25308. https:\/\/doi.org\/10.1371\/journal.pone.0025308 .","journal-title":"PLoS One"},{"issue":"11","key":"482_CR10","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1021\/cr940351u","volume":"99","author":"KE Uhrich","year":"1999","unstructured":"Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev. 1999;99(11):3181\u201398. https:\/\/doi.org\/10.1021\/cr940351u .","journal-title":"Chem Rev"},{"issue":"5","key":"482_CR11","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s13346-016-0313-z","volume":"6","author":"R Wyber","year":"2016","unstructured":"Wyber R, Boyd BJ, Colquhoun S, Currie BJ, Engel M, Kado J, et al. Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. Drug Deliv Transl Res. 2016;6(5):572\u20138. https:\/\/doi.org\/10.1007\/s13346-016-0313-z .","journal-title":"Drug Deliv Transl Res"},{"issue":"3","key":"482_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/(SICI)1521-3927(20000201)21:3<117::AID-MARC117>3.0.CO;2-X","volume":"21","author":"Y Ikada","year":"2000","unstructured":"Ikada Y, Tsuji H. Biodegradable polyesters for medical and ecological applications. Macromol Rapid Commun. 2000;21(3):117\u201332. https:\/\/doi.org\/10.1002\/(SICI)1521-3927(20000201)21:3<117::AID-MARC117>3.0.CO;2-X .","journal-title":"Macromol Rapid Commun"},{"issue":"3","key":"482_CR13","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377\u201397. https:\/\/doi.org\/10.3390\/polym3031377 .","journal-title":"Polymers (Basel)"},{"issue":"1","key":"482_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/pi.1697","volume":"54","author":"F Alexis","year":"2005","unstructured":"Alexis F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. Polym Int. 2005;54(1):36\u201346. https:\/\/doi.org\/10.1002\/pi.1697 .","journal-title":"Polym Int"},{"issue":"1\u20133","key":"482_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.schres.2007.08.003","volume":"98","author":"C Rabin","year":"2008","unstructured":"Rabin C, Liang Y, Ehrlichman RS, Budhian A, Metzger KL, Majewski-Tiedeken C, et al. In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res. 2008;98(1\u20133):66\u201378. https:\/\/doi.org\/10.1016\/j.schres.2007.08.003 .","journal-title":"Schizophr Res"},{"issue":"1","key":"482_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0378-5173(92)90367-B","volume":"78","author":"SS Sampath","year":"1992","unstructured":"Sampath SS, Garvin K, Robinson DH. Preparation and characterization of biodegradable poly(l-lactic acid) gentamicin delivery systems. Int J Pharm. 1992;78(1):165\u201374. https:\/\/doi.org\/10.1016\/0378-5173(92)90367-B .","journal-title":"Int J Pharm"},{"issue":"3","key":"482_CR17","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1208\/s12249-008-9126-9","volume":"9","author":"HA Gad","year":"2008","unstructured":"Gad HA, El-Nabarawi MA, Abd El-Hady SS. Formulation and evaluation of PLA and PLGA in situ implants containing secnidazole and\/or doxycycline for treatment of periodontitis. AAPS PharmSciTech. 2008;9(3):878\u201384. https:\/\/doi.org\/10.1208\/s12249-008-9126-9 .","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"482_CR18","first-page":"74","volume":"1","author":"K Malik","year":"2010","unstructured":"Malik K, et al. Atrigel: a potential parenteral controlled drug delivery system. Der Pharmacia Sinica. 2010;1(1):74\u201381.","journal-title":"Der Pharmacia Sinica"},{"issue":"9","key":"482_CR19","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.biomaterials.2005.09.019","volume":"27","author":"H Sun","year":"2006","unstructured":"Sun H, Mei L, Song C, Cui X, Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2006;27(9):1735\u201340. https:\/\/doi.org\/10.1016\/j.biomaterials.2005.09.019 .","journal-title":"Biomaterials"},{"key":"482_CR20","doi-asserted-by":"crossref","unstructured":"Dunn RL. The Atrigel drug delivery system. In: Drugs and the pharmaceutical sciences. New York: Dekker; 2003. p. 647\u201355.","DOI":"10.1201\/9780203910337.ch54"},{"key":"482_CR21","first-page":"85","volume":"2","author":"DB Patel","year":"2010","unstructured":"Patel DB. A review on atrigel drug delivery system. J Glob Pharma Technol. 2010;2:85\u201390.","journal-title":"J Glob Pharma Technol"},{"key":"482_CR22","unstructured":"Eligard\u00ae Full prescribing information sheet. Tolmar Pharmaceuticals. 04\/08\/2014]; http:\/\/www.eligard.com\/Docs\/Pdf\/TOLMAR%20Pharmaceuticals_Web_PI_05-07-14.pdf ]."},{"key":"482_CR23","unstructured":"Atridox\u00ae Full prescribing information sheet. Tolmar Pharmaceuticals. 04\/08\/2014]; http:\/\/www.carepathways.com\/DictionaryFDA2.cfm?RetDoc=http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050751s015lbl.pdf&drugname=ATRIDOX&ActiveIngredient=DOXYCYCLINEHYCLATE&type=Label ]."},{"issue":"7","key":"482_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-200241070-00003","volume":"41","author":"P Periti","year":"2002","unstructured":"Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet. 2002;41(7):485\u2013504. https:\/\/doi.org\/10.2165\/00003088-200241070-00003 .","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"482_CR25","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1021\/acs.molpharmaceut.5b00961","volume":"13","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Wischke C, Mittal S, Mitra A, Schwendeman SP. Design of controlled release PLGA microspheres for hydrophobic fenretinide. Mol Pharm. 2016;13(8):2622\u201330. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00961 .","journal-title":"Mol Pharm"},{"issue":"2","key":"482_CR26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","volume":"161","author":"S Kempe","year":"2012","unstructured":"Kempe S, Mader K. In situ forming implants\u2014an attractive formulation principle for parenteral depot formulations. J Control Release. 2012;161(2):668\u201379. https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.016 .","journal-title":"J Control Release"},{"issue":"2","key":"482_CR27","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/jps.21445","volume":"98","author":"C Manoharan","year":"2009","unstructured":"Manoharan C, Singh J. Insulin loaded PLGA microspheres: effect of zinc salts on encapsulation, release, and stability. J Pharm Sci. 2009;98(2):529\u201342. https:\/\/doi.org\/10.1002\/jps.21445 .","journal-title":"J Pharm Sci"},{"issue":"4\u20135","key":"482_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0141-8130(03)00081-3","volume":"33","author":"PG Navarro","year":"2003","unstructured":"Navarro PG, Bl\u00e1zquez IH, Osso BQ, Mart\u0131\u0301nez de las Parras PJ, Puentedura MIM, Garc\u0131\u0301a AAM. Penicillin degradation catalysed by Zn(II) ions in methanol. Int J Biol Macromol. 2003;33(4\u20135):159\u201366. https:\/\/doi.org\/10.1016\/S0141-8130(03)00081-3 .","journal-title":"Int J Biol Macromol"},{"key":"482_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-4614-0881-9_8","volume-title":"Fundamentals and applications of controlled release drug delivery","author":"C Wischke","year":"2012","unstructured":"Wischke C, Schwendeman SP. Degradable polymeric carriers for parenteral controlled drug delivery. In: Siepmann J, Siegel RA, Rathbone MJ, editors. Fundamentals and applications of controlled release drug delivery. Boston: Springer US; 2012. p. 171\u2013228. https:\/\/doi.org\/10.1007\/978-1-4614-0881-9_8 ."},{"issue":"sup118","key":"482_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3109\/00016925409170709","volume":"41","author":"VI Chapter","year":"1954","unstructured":"Chapter VI. Binding of penicillin to plasma protein. Acta Radiol. 1954;41(sup118):51\u20134.","journal-title":"Acta Radiol"},{"issue":"1","key":"482_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/infdis\/158.1.200","volume":"158","author":"SC Ebert","year":"1988","unstructured":"Ebert SC, Leggett J, Vogelman B, Craig WA. Evidence for a slow elimination phase for penicillin G. J Infect Dis. 1988;158(1):200\u20132. https:\/\/doi.org\/10.1093\/infdis\/158.1.200 .","journal-title":"J Infect Dis"},{"issue":"1","key":"482_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0022-3476(89)80352-X","volume":"115","author":"EL Kaplan","year":"1989","unstructured":"Kaplan EL, Berrios X, Speth J, Siefferman T, Guzman B, Quesny F. Pharmacokinetics of benzathine penicillin G: serum levels during the 28 days after intramuscular injection of 1,200,000 units. J Pediatr. 1989;115(1):146\u201350. https:\/\/doi.org\/10.1016\/S0022-3476(89)80352-X .","journal-title":"J Pediatr"}],"updated-by":[{"DOI":"10.1007\/s13346-018-0511-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000}}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-018-0482-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-018-0482-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-018-0482-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T04:57:49Z","timestamp":1570683469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-018-0482-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["482"],"URL":"https:\/\/doi.org\/10.1007\/s13346-018-0482-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13346-018-0511-y","asserted-by":"object"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"5 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J\u00fcrgen B. Bulitta\u2019s name was misspelled in the original version of the article. It is correct as reflected here. The original article has been revised.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jonathan Carapetis and Meru Sheel are investigators on a BPG projected funded by Novartis Institutes for BioMedical Research. Rosemary Wyber has provided technical advice to Pfizer on BPG but has not received funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}